FDA approves pediatric use of Dexcom’s G4 Platinum continuous glucose monitoring system

The U.S. Food and Drug Administration today approved the expanded use of the Dexcom G4 Platinum Continuous Monitoring System for patients with diabetes ages 2 to 17 years. The G4 Platinum System, which monitors blood glucose levels in people with diabetes, had been approved for patients ages 18 and older.

FDA Approves Hetlioz: first treatment for non-24 hour sleep-wake disorder in blind individuals

The U.S. Food and Drug Administration today approved Hetlioz (tasimelteon), a melatonin receptor agonist, to treat non-24- hour sleep-wake disorder (“non-24”) in totally blind individuals. Non-24 is a chronic circadian rhythm (body clock) disorder in the blind that causes problems with the timing of sleep. This is the first FDA approval of a treatment for the disorder.

FDA Statement on Western Sugar Cooperative voluntary recall of beet pulp and tailings

he U.S. Food and Drug Administration, in close coordination with the Wyoming Department of Agriculture (WDA) and the U.S. Department of Agriculture (USDA), has been working to address a tragic accident that occurred at the Western Sugar Cooperative’s Lovell, Wyo., manufacturing facility on Jan. 4, 2014.